EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries

M Zulf Mughal, Giampiero I Baroncelli, Carmen de Lucas-Collantes, Agnès Linglart, Andrea Magnolato, Adalbert Raimann, Fernando Santos, Dirk Schnabel, Nick Shaw, Ola Nilsson

Frontiers in Endocrinology · 2023

DOI: 10.3389/fendo.2022.1034580 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Endocrinology, 2023. Verfasst von M Zulf Mughal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Endocrinology and Metabolic Bone Diseases, Royal Manchester Children's Hospital, Manchester, United Kingdom. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin Pharmaceutical Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the objective of sharing these practice-based insights on the use of burosumab in children and adolescents with XLH. We attended two virtual meetings, then discussed key questions via Within3, a virtual online platform. Points of discussion related to patient selection criteria, burosumab starting dose, dose titration and treatment monitoring. Our discussions revealed that criteria for selecting children with XLH varied across Europe from all children above 1 year to only children with overt rickets despite conventional treatment being eligible. We initiated burosumab dosing according to guidance in the Summary of Product Characteristics, an international consensus statement from 2019 and local country guidelines. Dose titration was primarily guided by serum phosphate levels, with some centers also using the ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR). We monitored response to burosumab treatment clinically (growth, deformities, bone pain and physical functioning), radiologically (rickets and deformities) and biochemically (serum phosphate, alkaline phosphatase, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, urine calcium-creatinine ratio and TmP/GFR). Key suggestions made by our group were initiation of burosumab treatment in children as early as possible, from the age of 1 year, particularly in those with profound rickets, and a need for clinical studies on continuation of burosumab throughout adolescence and into adulthood.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsHumansChildAdolescentAntibodies, MonoclonalEuropePhosphatesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

XLHadolescentsburosumabchildrendosinggrowth plate closurericketstransition

Substanzen

Antibodies, MonoclonalPhosphatesburosumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Paediatric Endocrinology and Metabolic Bone Diseases, Royal Manchester Children's Hospital, Manchester, United Kingdom.
  • The Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.
  • Division of Pediatrics, Endocrine Unit, ERN-BOND Representative, Department of Obstetrics, Gynecology and Pediatrics, University-Hospital, Pisa, Italy.
  • Servicio Nefrología, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain.
  • AP-HP, Endocrinology and Diabetes for Children, Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Filière OSCAR, Bicêtre Paris Saclay Hospital, Paris, France.
  • Platform of Expertise for Rare Disorders, INSERM, Physiologie et Physiopathologie Endocriniennes, Paris Saclay University, Paris, France.

Förderung

  • Kyowa Kirin Pharmaceutical Development

Zitieren

APA

Mughal, M. Z., Baroncelli, G. I., de Lucas-Collantes, C., Linglart, A., Magnolato, A., Raimann, A., Santos, F., Schnabel, D., Shaw, N., & Nilsson, O. (2023). Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1034580

Vancouver

Mughal MZ, Baroncelli GI, de Lucas-Collantes C, Linglart A, Magnolato A, Raimann A, et al. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries. Frontiers in Endocrinology. 2023. doi:10.3389/fendo.2022.1034580

BibTeX
@article{Mughal2023,
  author = {Mughal, M Zulf and Baroncelli, Giampiero I and de Lucas-Collantes, Carmen and Linglart, Agnès and Magnolato, Andrea and Raimann, Adalbert and Santos, Fernando and Schnabel, Dirk and Shaw, Nick and Nilsson, Ola},
  title = {Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries},
  journal = {Frontiers in Endocrinology},
  year = {2023},
  doi = {10.3389/fendo.2022.1034580}
}
Kostenlos starten →